Register Log-in Investor Type

News

BioPharma updates on Lexicon

BioPharma Credit leads new $315m loan to Sebela

BioPharma updates on Lexicon – BioPharma Credit has updaed the market following an announcement from Lexicon Pharmaceuticals, Inc. Sanofi has made a notice of termination in relation to its collaboration and license agreement with Lexicon for the development and commercialization of Zynquista. Sanofi’s actions do not impact XERMELO(R) which is marketed by Lexicon in the US and is partnered outside the US with Ipsen. Lexicon and Sanofi have not yet finalized the details of the termination and this process might take several weeks or months.

BioPharama Credit funded US$124.5 million of a US$150.0 million loan to Lexicon that matures in December 2022. The loan is secured by substantially all of Lexicon’s assets, including its rights to XERMELO(R) as well as sotagliflozin (Zynquista).

XERMELO(R) was approved by the U.S. Food and Drug Administration on 28 February 2017 and by the European Commission on 19 September 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy. On 26 April 2019, Zynquista was approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index >= 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy. Outside of such approval in the EU, Zynquista is investigational and not approved by any other regulatory authority for type 1 or type 2 diabetes.

At this time, Pharmakon Advisors believes that there continues to be excess collateral value to fully support the loan. Pharmakon Advisors is actively monitoring the situation and will provide any updates in due course.

BPCR : BioPharma updates on Lexicon

Leave a Reply

Your email address will not be published. Required fields are marked *

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…